weekly, for 16 weeks. Follow-up Pap test conducted after the completion of therapy was negative for intraepithelial lesion or malignancy. All subsequent Pap smears, HPV testing and colposcopy findings in last five years came negative. Therefore, we were able to avoid further surgical treatment in this patient.

Conclusion Topical medical therapy with 5% imiquimod of cervical premalignant lesion, at this point, cannot replace surgical therapy but may be considered as an off-label treatment option for selected group of women who want to avoid further surgery, especially during standard observation after primary biopsy, as shown in our report.

Disclosures The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest or nonfinancial interest in the subject matter or materials discussed in this manuscript.

Abstracts

#910 HPV RELATED CERVICAL CARCINOSARcoma

Vid Jand*, Branko Cvjetan, Luka Kovac, Matija Barbic, Miha Blagajne, Kristina Dusanya Stacic, Marina Jakinovska Stefanovska, Katja Jakopic Macek, Natalja Kenda Suster, Tina Kusic, Spela SmrkoI, Mateja Lasic, Rossano Emanuele Carlo Distefano, Borislav Piril, Leon Meglic, Borut Kobal. University Medical Centre Ljubljana, Ljubljana, Slovenia; Ist. Patologia Ostetrica e Ginecologica, Catania, Italy; Department of General Surgery and Medical Surgical Specialties, Ljubljana, Slovenia; University of Catania, Ljubljana, Slovenia

Introduction/Background Cervical carcinosarcoma is a rare and aggressive malignancy that accounts for less than 1% of all cervical cancers. There is also evidence to suggest that human papillomavirus (HPV) infection may play a role in the development of cervical carcinosarcoma. Although the exact mechanisms by which HPV may contribute to the development of carcinosarcomas are not fully understood, some studies have suggested that high-risk HPV types may be involved in the pathogenesis of these tumours.

Methodology A comprehensive literature research of studies on rare pathological entity was performed in the Pubmed Database for the literature published in the last ten years. Analysis of our case in a young patient was included.

Results Given the exceptional rarity of this histopathological entity evidence is still missing regarding its risk factors, pathogenesis, management and prognostic factors. It affects mainly postmenopausal patients and less than 10 cases have been reported on women younger than 40 years old, which complicates its management when dealing with patients in their fertile period as in our case. We report a case of a 26 year old woman who was referred to our clinic for a cervical lesion.

Conclusion Due to the rarity of cervical carcinosarcoma and lack of abundant case study reports, uniform clinical guidelines for treatment following surgical resection remain unclear. However, this case study suggests that radical surgical treatment of this disease with negative margins in young patients with early-stage disease can be sufficient in treating cervical carcinosarcoma, despite their typical aggressive nature.

Disclosures The authors declare no conflicts of interests.

#893 NON-INFERIOR SURVIVAL OUTCOMES BETWEEN LAPAROSCOPIC AND OPEN RADICAL HYSTERECTOMY IN EARLY CERVICAL CANCER WITH INCIDENTALLY IDENTIFIED PATHOLOGIC HIGH-RISK FACTORS

Seungjun Lee*, Myung Eun Jang, Dong Hoon Suh, Hee Seung Kim, Kidong Kim, Hyun Hoon Chung, Jae Hong No, Yong Beom Kim, Noh Hyun Park, Chel Hun Choi, Maria Lee. Seoul National University Hospital, Seoul, South Korea; Seoul National University Bundang Hospital, Seongnam, South Korea; Samsung Medical Center, Seoul, South Korea

Introduction/Background Previously, we suggested that patients with cervical cancer with tumors ≤2 cm on preoperative magnetic resonance imaging (MRI) are safe candidates for laparoscopic radical hysterectomy (LRH). Here, we aimed to investigate whether LRH deteriorates the prognosis of patients with incidentally identified high-risk factors on pathologic examination.

Methodology We identified patients with 2009 FIGO stage IB1 cervical cancer who underwent Type C LRH or open radical hysterectomy (ORH) at three tertiary hospitals between 2007 and 2018. Those with a tumor ≤2 cm on preoperative MRI who adhered to the practice guidelines for adjunct treatment were included. Survival outcomes were compared between the LRH and ORH groups. Subgroup analyses were conducted according to presence of lymph node metastasis (LNM) and/or parametrial invasion (PMI).

Results In total, 498 patients were included: 299 in the LRH group and 199 in the ORH group. The ORH and LRH groups showed similar 5-year progression-free survival (PFS) (92.9% vs. 91.6%; P=0.615) and 5-year overall survival (OS) rates (96.8% vs. 97.2%; P=0.439). On pathologic examination, 49 (9.8%) and 16 (3.2%) patients had LNM and PMI, respectively, and 10 (2.0%) had both. In the LNM subgroup, 5-year PFS rate was not significantly different between the ORH and LRH groups (91.7% vs. 73.2%; P=0.169). In the PMI subgroup, no difference in PFS was observed between the two groups (P=0.893).

Conclusion LRH might not deteriorate recurrence and mortality rates in CC patients with a tumor size ≤2 cm when adjuvant treatment is appropriately administered, even if pathologic LNM and PMI are incidentally identified.

Disclosures Nothing to disclose.

#915 RADICAL VAGINAL TRACHELECTOMY – WHAT MAKES IT RADICAL AND IS IT SAFE TO STEP DOWN ?

Irina Cepraga*, Angela Kather, Valentina Auletta, Davit Bokhua, Anke Esber, Ingo Runnebaum. University Hospital Jena, Jena, Germany

Introduction/Background Radical vaginal trachelectomy (RVT) is a safe and viable treatment option for patients with early stage cervical cancer wishing to preserve fertility. We performed a retrospective monocentric study to describe the detection rate of sentinel biopsy, frequency of residual tumor in trachelectomy specimen and the impact of changes in FIGO staging.

Methodology 107 patients who underwent RVT at University Hospital Jena (1998–2020) were included. Inclusion criteria: 21 to 41 years, cervical cancer stage Ia1 to Ib2, any tumor size, regardless of neoadjuvant chemotherapy, regardless of...
QUALITY ASSURANCE FOR CLINICAL PRACTICE IN LARGE CELL NEUROENDOCRINE CARCINOMA OF THE CERVIX: ABOUT THREE CASES

Souha Jaouadi*, Med Amine Bouida, Marwa Aloui, Ghada Sahraoui, Maher Slimane, Riadh Chargui, Karima Mhad, Tarek Dhiab. Surgical oncology department, Salah Azaiez institute, Tunis, Tunisia; Pathology department, Institut Salah Azaiez, Tunis, Tunisia

10.1136/ijgc-2023-ESGO.207

LARGE CELL NEUROENDOCRINE CARCINOMA OF THE CERVIX: ABOUT THREE CASES

Sara Ramella, Teresa Insero, Marta Moraschi, Valentina Pirozzi Palmese, Paola Martucci, Rita Alaimo, Edy Ippolito, Valerio Marè, Daniele Carlotti, Michele Fiore, Lisa Vicenzi*, Roberta Guarnaccia, Lisa Vicenzi, Daniele Carlotti, Michele Fiore.

1Medicine and Surgery, Rome, Italy; 2Fondazione Policlinico Campus Bio-Medico, Rome, Italy

10.1136/ijgc-2023-ESGO.206

QUALITY ASSURANCE FOR CLINICAL PRACTICE IN CERVICAL CANCER BRACHYTHERAPY WITH IR-192 SOURCE: IN VIVO DOSIMETRY WITH QED DIODES

Valerio Marè, Daniele Carlotti, Michele Fiore, Lisa Vicenzi*, Roberta Guarnaccia, Paolo Matteucci, Aurelia Isarò, Gian Marco Petrianni, Viera Cimigliano, Marta Monashli, Valentina Pirozzi Palmese, Paola Marucci, Rita Alaimo, Edy Ippolito, Sara Ramella, Teresa Insero.

1Fondazione Policlinico Campus Bio-Medico; Università Campus Bio-Medico di Roma, Medicine and Surgery, Rome, Italy

10.1136/ijgc-2023-ESGO.208

Introduction/Background Large cell neuroendocrine carcinoma (LCNEC) is a rare subtype of cervical cancer that accounts for approximately 2–5% of all cervical cancer cases. LCNEC is characterized by a high degree of aggressiveness, early metastasis, and poor prognosis.

Methodology In this abstract, we present three cases of large cell neuroendocrine carcinoma, each with a unique clinical presentation.

Results Case 1: A 50-year-old woman presented with abnormal vaginal bleeding and pelvic pain. Further investigation revealed a large tumor in the cervix. A biopsy confirmed the diagnosis of LCNEC. The patient underwent Neoadjuvant chemotherapy and brachytherapy, but developed metastases to the lungs and liver within six months of initial diagnosis.

Case 2: A 51-year-old woman presented with postmenopausal bleeding and was diagnosed with LCNEC on biopsy. Further imaging studies showed the presence of metastases to the lymph nodes and liver. The patient was treated with chemotherapy and radiotherapy, but succumbed to the disease after 18 months.

Case 3: A 47-year-old woman presented with recurrent vaginal bleeding and was diagnosed with LCNEC on biopsy. Further evaluation revealed metastases to the lungs, liver, and bone.

The patient underwent chemotherapy, but unfortunately experienced disease progression and passed away within a year of initial diagnosis.

Conclusion LCNEC is a rare and aggressive subtype of cervical cancer that poses significant challenges in diagnosis and management. The prognosis for patients with NECC is poor, with a high risk of recurrence and metastasis. While surgery and lymphadenectomy have been found to significantly impact survival rates, chemotherapy and radiotherapy appear to have little to no effect on prognosis.

Disclosures All authors declare that they have no conflicts of interest.